戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ed to address questions in basic science and experimental medicine.
2  clinician who had a strong interest in true experimental medicine.
3 c agents will yield significant benefits for experimental medicine.
4 els of pathology and quantitative assays for experimental medicine.
5 as reported by Peyton Rous in the Journal of Experimental Medicine 100 years ago, opened the field of
6                                      In this experimental medicine add-on study to a randomized, doub
7  rationale for the implementation of a broad experimental medicine and clinical trials agenda.
8 ttus norvegicus) is an indispensable tool in experimental medicine and drug development, having made
9 -target identification, the molecule itself, experimental medicine, and larger-scale clinical testing
10 -The Journal of Cell Biology, The Journal of Experimental Medicine, and The Journal of General Physio
11             In this Viewpoint we discuss how experimental medicine applied in the setting of clinical
12 sing this critical knowledge gap, we use the experimental medicine approach of immunomodulatory drug
13       This review employs four stages of the experimental medicine approach to answer these questions
14 the absence of these confounders, we take an experimental medicine approach to examine the in vivo ut
15                The present study employed an experimental medicine approach to test the effects of 4
16 ltimately, the incorporation of big data and experimental medicine approaches should aim to reduce th
17                   The applications of PET to experimental medicine are summarised, and we cover how t
18 o represented a major advance in biology and experimental medicine, as it enabled the routine manipul
19  an assistant professor in the Department of Experimental Medicine at the University of California, S
20          In a recent paper in the Journal of Experimental Medicine, Campbell and colleagues demonstra
21              In this issue of the Journal of Experimental Medicine, Cao et al. demonstrate that the c
22                 This issue of the Journal of Experimental Medicine celebrates and honors the life of
23                                              Experimental medicine (EM) offers an approach that can h
24                  The Hunterian Laboratory of Experimental Medicine, established at the Johns Hopkins
25      Gaffen, and published in The Journal of Experimental Medicine in 2009.
26                 Another approach may involve experimental medicine models, which aim to develop objec
27 litis in Monkeys" appeared in the Journal of Experimental Medicine on February 21, 1933.
28  psychostimulant, amphetamine, is used as an Experimental Medicine probe in patients with schizophren
29                      In 1944, the Journal of Experimental Medicine published the groundbreaking disco
30 ent paper by Sirois et al. in The Journal of Experimental Medicine reports that the receptor for adva
31 ce-based risks of symptom exacerbation in an Experimental Medicine setting vs. risks associated with
32 lopments include the increasing use of human experimental medicine strategies before phase III trials
33  PET could support translational studies and experimental medicine strategies for new disease-modifyi
34 t and sufficiently scalable to be viable for experimental medicine studies and clinical trials.
35 d controlled trials with clinical endpoints, experimental medicine studies are focusing on mechanisti
36 l and correspondingly, the value of detailed experimental medicine studies early in vaccine developme
37 associated amyloid-beta species will require experimental medicine studies in humans.
38                                              Experimental Medicine studies in psychiatric populations
39 phrenia patients participated in one or more Experimental Medicine studies involving limited doses of
40  pharmacodynamic studies is enabling imaging experimental medicine studies to assess the potential ef
41 dioligand is available, be employed in small experimental medicine studies to provide plasma pharmaco
42  dementia, to facilitate clinical trials and experimental medicine studies.
43 ve physiology that support translational and experimental medicine studies.
44 ls can be integrated for use in clinical and experimental medicine studies.
45 nflammatory role in these disorders includes experimental-medicine studies with IFN-alpha and endotox
46                                  The present experimental medicine study examined whether diazepam ca
47                                  The current experimental medicine study reports the effects of a com
48     In this double-blind, placebo-controlled experimental medicine study, healthy adults were randomi
49                                In a separate experimental medicine study, patients with BD were rando
50 rocesses suggests it could be a valuable new experimental medicine tool across neuropsychiatric and n
51 , we discuss the reasons behind the focus on experimental medicine trials, the strengths and weakness
52 g a new funding programme that will focus on experimental medicine trials.
53 hese will reduce the time, risk and costs of experimental medicine trials.
54 subacute, or long-term consequences from the Experimental Medicine use of amphetamine in antipsychoti